Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.
about
Risk calculators and updated tools to select and plan a repeat biopsy for prostate cancer detectionExternal Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC.Gleason 6 Prostate Cancer: Translating Biology into Population Health.The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape.Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies.Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators.Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian CohortNet benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests.Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer.Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making.Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculatorRisk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS.Novel biomarkers for the detection of prostate cancer.The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used?Prostate-specific antigen screening, why have the guidelines changed?Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.Role of mpMRI of the prostate in screening for prostate cancer.Biomarkers in localized prostate cancer.Atypical small acinar proliferation (ASAP): Is a repeat biopsy necessary ASAP? A multi-institutional review.Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI/US fusion-guided biopsy.European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume.Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel.Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer.Atypical Small Acinar Proliferation: Repeat Biopsy and Detection of High Grade Prostate Cancer.Recommandations de l’Association des urologues du Canada sur le dépistage et le diagnostic précoce du cancer de la prostate.Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.Atypical small acinar proliferation at index prostate biopsy: rethinking the re-biopsy paradigm.The molecular biology of prostate cancer: current understanding and clinical implications.Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology.Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome.Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer.Multivariable risk-based patient selection for prostate biopsy in a primary health care setting: referral rate and biopsy results from a urology outpatient clinic.MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy
P2860
Q27027085-38E58C2A-E790-4242-B24B-8A043D82816CQ31096808-5B0DC2B0-23ED-4242-A21C-50C6313C0AFFQ34470640-A00271AE-7425-4CC8-9495-E3FF8903AAC6Q35762868-4CB14CE7-DD7D-4800-9819-A0EFC2E930EBQ35852107-1D3DD28F-ABAD-4D1D-A1BB-2E2477AD4DB8Q35940811-BF5F0418-7D63-418B-9762-5F5D962360B8Q36238237-6466A00A-0EFD-46C3-B0A5-D4BC713ED8C5Q36495833-1518F7E8-5D24-466C-BDEC-4106A4682FC8Q37043425-EB9B2BAF-DEB2-414F-9853-DBBA554D107DQ37241363-6D86B6B8-5438-4DC7-9812-14997CDCDEDFQ37279076-C21979B4-1173-4330-997A-6DB218ACF919Q37418080-468430F0-C6A3-447A-9D2F-56E980A5F2E6Q37563750-51A2EB02-77C6-4F43-AD70-F0AA8F78CA51Q37708174-3AAB82DB-EB74-4002-8039-92430DFA8276Q38211603-3E2ECAB9-387E-4C2F-AEE2-9194B10C4DDDQ38259244-B7828B7F-D6BD-42FD-B622-46B0E90A862EQ38568275-CB992480-66A8-4E63-9390-FDA6538F1A4EQ38671170-0B86B8D6-275A-4960-BBD7-259DA87D85B2Q38697114-238E94CF-464A-4DFA-A22C-40F50FB7F88DQ38726541-1801144F-C212-4570-8B00-E781E59CA8F7Q38789338-D0B118C8-D95C-49EC-933B-30694152C8EBQ38950693-84350CBB-CAE8-439F-A55C-54C549B3C5E0Q40034472-B3AE0091-F50E-4B7D-9AD3-2DD5794202ADQ40385170-5CE7EB7A-7A93-440A-A956-FD947DA720D7Q40417671-D0CE4603-FC0C-4424-958A-0123E6CE3F4BQ40852349-771D018C-EAD9-4CBC-8962-AA417D18DF24Q42247367-A7B93816-0E63-43A3-9261-B0AA9A2FA996Q47123251-1AFE0221-05CB-49F0-8EC2-4C0C2D40DD4EQ47726986-A5B88FB1-6DF1-414D-A2C2-7CB38F8930B5Q48139219-68723558-F562-45B5-A5A9-BDB6D7924CD5Q49546811-09B6EAF4-C533-4F75-8B85-AC93D230A581Q50107743-5A529B03-6D8A-45FB-9386-1AAA1052D67DQ52841824-CFF7BD41-67D4-4881-AF44-D3A7BC5FFAB4Q54996710-4BED37C5-CF0F-4F2C-B1B5-2973388B496BQ55007094-DFC334A2-E041-43ED-8C15-0E354C128824Q55139905-CE36E827-B992-46A2-9500-A1CFFE4A0EA8Q57112037-7E806448-0199-4108-86BD-DFFB05A698ED
P2860
Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Prostate Cancer Prevention Tri ...... vs high-grade prostate cancer.
@ast
Prostate Cancer Prevention Tri ...... vs high-grade prostate cancer.
@en
type
label
Prostate Cancer Prevention Tri ...... vs high-grade prostate cancer.
@ast
Prostate Cancer Prevention Tri ...... vs high-grade prostate cancer.
@en
prefLabel
Prostate Cancer Prevention Tri ...... vs high-grade prostate cancer.
@ast
Prostate Cancer Prevention Tri ...... vs high-grade prostate cancer.
@en
P2093
P2860
P1433
P1476
Prostate Cancer Prevention Tri ...... vs high-grade prostate cancer.
@en
P2093
Ian M Thompson
Javier Hernandez
John T Wei
Josef Hoefler
Lori J Sokoll
Martin G Sanda
Phyllis J Goodman
Robin J Leach
Sebastian Bock
P2860
P304
P356
10.1016/J.UROLOGY.2014.02.035
P407
P577
2014-06-01T00:00:00Z